Allergy Unit, Complesso Integrato Columbus, Rome, Italy; IRCCS Oasi Maria S.S., Troina, Italy.
Allergy Unit, Complesso Integrato Columbus, Rome, Italy.
J Allergy Clin Immunol. 2016 Jul;138(1):179-186. doi: 10.1016/j.jaci.2016.01.025. Epub 2016 Mar 23.
The few studies performed in adults with T cell-mediated hypersensitivity to penicillins have found a rate of cross-reactivity with cephalosporins ranging from 2.8% to 31.2% and an absence of cross-reactivity with aztreonam.
We sought to evaluate the possibility of using cephalosporins and aztreonam in subjects with documented delayed hypersensitivity to penicillins who especially require them.
We conducted a prospective study of 214 consecutive subjects who had 307 nonimmediate reactions to penicillins (almost exclusively aminopenicillins) and had positive patch test and/or delayed-reading skin test responses to at least 1 penicillin reagent. To assess cross-reactivity with cephalosporins and aztreonam and the tolerability of such alternative β-lactams, all subjects underwent skin tests with cephalexin, cefaclor, cefadroxil, cefuroxime, ceftriaxone, and aztreonam. Subjects with negative responses were challenged with the alternative β-lactams concerned.
All subjects had negative skin test results to cefuroxime, ceftriaxone, and aztreonam and tolerated challenges. Forty (18.7%) of the 214 subjects had positive skin test responses to at least 1 aminocephalosporin. Of the 174 subjects with negative responses, 170 underwent challenges; 1 reacted to cefaclor.
These data demonstrate a rate of cross-reactivity between aminopenicillins and aminocephalosporins (ie, cephalexin, cefaclor, and cefadroxil) of around 20%, as well as the absence of cross-reactivity between penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-mediated hypersensitivity to penicillins, almost exclusively aminopenicillins. Therefore these subjects could be treated with cefuroxime, ceftriaxone, and aztreonam. In those who especially require cephalosporin or aztreonam treatment, however, we recommend pretreatment skin tests because negative responses indicate tolerability.
少数针对 T 细胞介导的青霉素过敏成人进行的研究发现,头孢菌素类药物的交叉反应率为 2.8%至 31.2%,而与氨曲南无交叉反应。
我们旨在评估在有青霉素迟发型过敏史且特别需要使用头孢菌素类和氨曲南的患者中使用这些药物的可能性。
我们对 214 例连续患者进行了前瞻性研究,这些患者对青霉素(几乎均为氨基青霉素)有 307 次非即刻反应,且对至少 1 种青霉素试剂的斑贴试验和(或)迟发型皮肤试验呈阳性反应。为评估头孢菌素类药物和氨曲南的交叉反应性以及这些替代β-内酰胺类药物的耐受性,所有患者均接受头孢氨苄、头孢克洛、头孢羟氨苄、头孢呋辛、头孢曲松和氨曲南的皮肤试验。对阴性反应患者进行了相关替代β-内酰胺类药物的挑战试验。
所有患者的头孢呋辛、头孢曲松和氨曲南皮肤试验结果均为阴性,且可耐受相应的挑战试验。214 例患者中,40 例(18.7%)至少对 1 种氨基头孢菌素呈阳性皮肤反应。174 例阴性反应患者中,170 例接受了挑战试验,其中 1 例对头孢克洛呈阳性反应。
这些数据表明,氨基青霉素和氨基头孢菌素(即头孢氨苄、头孢克洛和头孢羟氨苄)之间的交叉反应率约为 20%,而青霉素与头孢呋辛、头孢曲松和氨曲南之间在所有青霉素 T 细胞介导过敏的患者中均无交叉反应,这些患者几乎仅对氨基青霉素过敏。因此,这些患者可以使用头孢呋辛、头孢曲松和氨曲南进行治疗。然而,对于那些特别需要头孢菌素或氨曲南治疗的患者,我们建议进行皮试预处理,因为阴性反应表明可耐受相应药物。